Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 16/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31384147 | 1.00 | NLRP3 (0.43) | NLRP3ABCB1OPRM1OPRD1OPRK1 | |
| Taxine Ii SCHEMBL30563046 | 0.80 | — | — | |
| Taxinine A SCHEMBL30495377 | 0.80 | RAB9A (0.32) | ABCB1 | |
| SCHEMBL44737 | 0.72 | NLRP3 (0.47) | NLRP3ABCB1OPRM1OPRD1OPRK1 | |
| Taxuspine F SCHEMBL30602496 | 0.68 | RAB9A (0.31) | — | |
| SCHEMBL29394113 | 0.68 | ABCB1 (0.31) | ABCB1CYP2C19 | |
| SCHEMBL44183 | 0.67 | ABCB1 (0.41) | NLRP3ABCB1 | |
| SCHEMBL29425006 | 0.66 | NLRP3 (0.38) | NLRP3ABCB1CYP2C19 | |
| Taxagifine SCHEMBL29520283 | 0.66 | ABCB1 (0.40) | NLRP3ABCB1CYP2C19 | |
| Taxagifine SCHEMBL28964410 | 0.66 | ABCB1 (0.40) | NLRP3ABCB1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250000924-A1 | Composition for the prevention, improvement or treatment of allergic disease comprising an extract of Taxus cuspidata as an active ingredient | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2025-01-02 | — | — | US | claimed |
| CN-104606677-B | A kind of taxanes composition for improving paclitaxel oral bioavilability and its application | 中山大学 | 2018-04-03 | — | — | CN | claimed |
| EP-2832371-B1 | APPLICATION OF GASTRODIN AS SOLUBILIZER AND METHOD FOR PREPARING INJECTION OR POWDER FOR INJECTION | KPC PHARMACEUTICALS INC (CN) | 2017-02-01 | — | — | EP | claimed |
| CN-106265598-A | A kind of based on biological functionalized nano silver paclitaxel loaded or the targeted delivery systems of its analog | 广东工业大学 | 2017-01-04 | — | — | CN | claimed |
| CN-104606677-A | Taxol oral bioavailability improving taxane composition and application | UNIV SUN YAT SEN | 2015-05-13 | — | — | CN | claimed |
| EP-2832371-A1 | APPLICATION OF GASTRODIN AS SOLUBILIZER AND METHOD FOR PREPARING INJECTION OR POWDER FOR INJECTION | Kunming Pharmaceutical Corp. (CN) | 2015-02-04 | — | — | EP | claimed |
| US-8710013-B2 | Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use | ANGIOCHEM INC. (CA) | 2014-04-29 | — | — | US | claimed |
| US-7846666-B2 | Methods of RNA amplification in the presence of DNA | NUGEN TECHNOLOGIES, INC. (US) | 2010-12-07 | — | — | US | claimed |
| WO-2009117698-A2 | METHODS OF RNA AMPLIFICATION IN THE PRESENCE OF DNA | NUGEN TECHNOLOGIES, INC. (US) | 2009-09-24 | — | — | WO | claimed |
| US-20090239232-A1 | METHODS OF RNA AMPLIFICATION IN THE PRESENCE OF DNA | NUGEN TECHNOLOGIES INC (US) | 2009-09-24 | — | — | US | claimed |
| US-20080075794-A1 | Mixture of natural plant extracts comprising extracts from Taxus and Thymus; capable of strong antimicrobial ability as well as the elimination of foul odors | BAE CHANGSOON | 2008-03-27 | — | — | US | claimed |
| CN-1256308-C | Yew genus plant extract and its extraction method and application | HEILONGJIANG YEW TECHNOLOGY CO (CN) | 2006-05-17 | — | — | CN | claimed |
| CN-1594247-A | Yew genus plant extract and its extraction method and application | HEILONGJIANG YEW SCIENCE AND T (CN) | 2005-03-16 | — | — | CN | claimed |
| CN-1397233-A | Natural Japanese yew beverage | LI MEISHENG (CN) | 2003-02-19 | — | — | CN | claimed |
| CN-1307890-A | Tuberculosis-resisting toxol medicine | LI MEISHENG (CN) | 2001-08-15 | — | — | CN | claimed |
| CN-1301562-A | Anticancer Chinese medicine yew liquid | LI MEISHENG (CN) | 2001-07-04 | — | — | CN | claimed |
| CN-1301542-A | Taxad medicine wine | LI MEISHENG (CN) | 2001-07-04 | — | — | CN | claimed |
| CN-122070906-A | Pharmaceutical composition of paclitaxel conjugate and preparation method thereof | 北京盛诺基医药科技股份有限公司 | 2026-05-22 | — | — | CN | disclosed |
| US-5481010-A | FOR USE IN THERAPY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1996-01-02 | — | — | US | disclosed |
| WO-1993002064-A1 | NOVEL 7-DEACETOXY BACCATINE IV DERIVATIVE, AND PREPARATION AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1993-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000924-A1 | Composition for the prevention, improvement or treatment of allergic disease comprising an extract of Taxus cuspidata as an active ingredient | SERPINB1, TSLP, CMA1 | NLRP3 1715/4885ABCB1 123/4885OPRM1 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.